Navigation Links
Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures

FREMONT, Calif., Feb. 26 /PRNewswire/ -- Biomerix Corporation announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market REVIVE(TM). Constructed using the Biomerix Biomaterial(TM), REVIVE acts as a tissue scaffold facilitating rapid tissue ingrowth and can be utilized in a variety of soft tissue repair procedures, including the repair of inguinal hernias.

With more than 700,000 procedures per year, inguinal hernia repair is one of the most common surgeries in the U.S.(1) Hernia repair typically involves the use of a mesh to reinforce and support the surrounding tissue. REVIVE is designed to minimize the scarring response that results from implantation of a mesh, which studies have shown can lead to persistent groin pain in 30% of patients at one year(2). Clinical feedback has confirmed REVIVE offers excellent conformability to the defect and ease of handling.(3)

"Biomerix is poised for rapid growth over the course of the next few years. The company plans to launch numerous products across a range of therapeutic areas by capitalizing on its novel Biomerix Biomaterial platform technology. REVIVE is specifically designed to support tissue remodeling by enhancing the soft tissue wound healing process and thereby improves clinical outcomes," stated Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation.

The company has initiated a market launch of REVIVE in the U.S. through a small direct sales force and plans to expand the group over time as additional products are brought to market.

About Biomerix Corporation

Biomerix Corporation develops and manufactures a broad portfolio of implantable medical devices based on its proprietary Biomerix Biomaterial(TM) platform technology. Unique to the Biomerix Biomaterial, is its ability to facilitate fibrovascular tissue in-growth and improve wound healing with a minimal inflammatory response, leading to better clinical outcomes. Biomerix strives to improve patient outcomes through the development of medical devices for soft tissue repair, neurovascular embolization, spine annular repair, cardiovascular repair and women's health indications, utilizing its novel biomaterial.

For more information please call 888.308.3620 or visit

  1. Millenium U.S. Markets for Soft Tissue Repair 2008.
  2. Bay-Nielsen M et. al., "Pain and functional impairment 1 year after inguinal herniorrhaphy: a nationwide questionnaire study," Ann Surg 2001 Jan;233(1):1-7.
  3. Data on file with Biomerix Corporation

SOURCE Biomerix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... (AMA) and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with ... and other AMA team leaders met with OPBAP leaders Capt. Karl Minter and ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):